JNJ · News · 20260828N

China Icotyde Approval

JOHNSON & JOHNSON · 2026-08-28 · Importance 38 · Surprise 60

Johnson & Johnson received approval from China’s National Medical Products Administration for Icotyde, an oral psoriasis treatment developed with Protagonist Therapeutics. Icotyde is intended as a once-daily treatment for plaque psoriasis, an autoimmune skin disease. The approval expands the companies’ commercial and regulatory position in China and represents a significant milestone for the product in that market.

Key facts

• The drug Icotyde is intended as a once-daily treatment for plaque psoriasis. source